Quantum BioPharma Provides Corporate Update

Corporate Updates - Quantum BioPharma Ltd. has announced the cancellation of 7,692 warrants previously granted to Michael (Zappy) Zapolin, as they no longer served as a realistic incentive [2][3] - The company has granted 7,692 stock options to Mr. Zapolin with an exercise price of C$6.60 per Class B Share, expiring on March 7, 2027 [4] - The option grant is classified as a related party transaction, requiring minority shareholder approval and a formal valuation, but the Board determined it was exempt from these requirements [5] Financial Activities - On March 6, 2025, the company closed a fourth tranche of a previously announced offering, issuing 100 Debenture Units for$100,000, which will be used for business development and working capital [6] - The company may close additional tranches with an increased conversion price of $6.60 and an increased exercise price per Warrant Share of$7.00 [6] Company Overview - Quantum BioPharma focuses on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation [8][9] - The company retains a 25.71% ownership in Celly Nutrition Corp., which includes royalty payments of 7% of sales from its product unbuzzd™ until total payments reach $250 million, after which the royalty will drop to 3% [9]